

## **Supplementary Figure S1** HeLa 0 hour 24 hour 48 hour **DMSO** P5 (2 µM) P5 (3 µM) C B HeLa 4e+6 **DMSO** Parental cell viability (%) Wound enclosure area (unit) Hela (MTT) P5 - 2 μΜ Ρ5 - 3 μΜ 100 3e+6 80 2e+6 60 ŊS 40 1e+6 20 IC<sub>50</sub>: 2.648 nM 24 hours 48 hours Paclitaxel concentration (nM) D Hela CSC (MTT) HeLa CSCs viability (%) 100 Paclitaxel (IC50 = 737.9 nM)75 Paclitaxel + P5 **50** (IC50 = 3.02 nM)25 Log (Paclitaxel concentration) nM

A



В



## **Supplementary Figure S1**

(A) The wound healing assay shows the N-phenyl pyrazoline 5 treatment significantly reduced the migration ability in HeLa cells with the doses 2  $\mu$ M and 3  $\mu$ M. (B) The quantification graph of the previous figure. (C) To evaluate the cancer stem cell characteristic (chemoresistant), the MTT assays were performed using the HeLa parental cells and harvested HeLa cells from hanging drop 3D culture. The parental cells show the IC<sub>50</sub> was 2.648 nM against paclitaxel. (D) The harvested HeLa cells from hanging drop 3D culture were more resistant to paclitaxel with IC<sub>50</sub> 737.9 nM. Intriguingly, the N-phenyl pyrazoline 5 treatment sensitized the resistant HeLa cells to paclitaxel. \* p-value < 0.05, \*\* p < 0.01, \*\*\* p < 0.001; NS, not significant.

## **Supplementary Figure S2**

The kaplan meier overall survival analysis was performed using the cervical cancer patients dataset (https://xenabrowser.net/).

(A) The EGFR high expression was significantly associated with poor survival of cervical cancer patients, (B) meanwhile, the ERBB2 has no prognostic value in cervical cancer patients.